We are delighted to announce that Dr. Clint Stalnecker will join the Department of Biochemistry and Biophysics as a tenure-track Assistant Professor, effective December 15, 2025. He will also be appointed as a full member of the Lineberger Comprehensive Cancer Center.
Dr. Stalnecker’s research centers on signaling dynamics associated with resistance to targeted therapies in cancer, with a particular focus on how cancer cells bypass therapies targeting the KRAS signaling pathway using chemical biology approaches and translational models. His work aims to advance translational therapies and discover new therapeutic targets and signaling paradigms that support cancer cell growth.
Dr. Stalnecker earned his B.S. in Biochemistry from Albright College, followed by a Ph.D. in Chemical Biology from Cornell University, where he focused on understanding oncogene-induced altered metabolism in cancer and strategies to target aberrant glutamine metabolism. He recently completed his postdoctoral training at UNC’s Lineberger Comprehensive Cancer Center under Dr. Channing Der, determining the KRAS-driven transcriptome, proteome, and phosphoproteome driving KRAS mutant cancers and resistance mechanisms to therapies targeting KRAS.
At UNC, The Stalnecker Lab will employ a multi-omics systems-level approach to understand therapeutic resistance, integrating proteomics and phosphoproteomics, transcriptional networks, chemical and genetic library screens, and translational models to define new signaling networks in cancer.
Dr. Stalnecker will welcome rotation students in Spring 2026.